Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OneSource Specialty PharmaNSE:ONESOURCE -2.14%8 PS Ratio is 11.04 as of Aug. 27, 2026, which is 16% below its 10-year median of 13.17. GuruFocus rates NSE:ONESOURCE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 931 Biotechnology companies, OneSource Specialty Pharma ranks worse than 53.6% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, OneSource Specialty Pharma's share price is ₹1483.60.
OneSource Specialty Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹134.37. Hence, OneSource Specialty Pharma's PS Ratio for today is 11.04.
The historical rank and industry rank for OneSource Specialty Pharma's PS Ratio or its related term are showing as below:
NSE:ONESOURCE'
s PS Ratio Range Over the Past 10 Years
Min: 8.62 Med: 13.17 Max: 19.63
Current: 11.04
During the past 4 years, OneSource Specialty Pharma's highest PS Ratio was 19.63. The lowest was 8.62. And the median was 13.17.
NSE:ONESOURCE's PS Ratio is ranked worse than 53.6% of 931
companies
in the Biotechnology industry
Industry Median: 9.49
vs NSE:ONESOURCE: 11.04
During the past 4 years, OneSource Specialty Pharma's highest 3-Year average Revenue per Share Growth Rate was 232.20% per year. The lowest was 232.20% per year. And the median was 232.20% per year.
OneSource Specialty Pharma (NSE:ONESOURCE) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
OneSource Specialty Pharma PS Ratio Related Terms
OneSource Specialty Pharma PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ONESOURCE vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, OneSource Specialty Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OneSource Specialty Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OneSource Specialty Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where OneSource Specialty Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
OneSource Specialty Pharma's Share Price of today is ₹1483.60. OneSource Specialty Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹134.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
OneSource Specialty Pharma (NSE:ONESOURCE) has a PS Ratio of 11.04 as of Aug. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on OneSource Specialty Pharma and its competitors. This is 16% below median its historical median of 13.17. Over the past decade, OneSource Specialty Pharma's PS Ratio has ranged from 8.62 to 19.63. According to the industry distribution chart, OneSource Specialty Pharma ranks #499 out of 931 companies in the Biotechnology industry, placing it in the top 53.6%.
Is OneSource Specialty Pharma's PS Ratio too high?
OneSource Specialty Pharma's current PS Ratio of 11.04 is 16% below median its 10-year median of 13.17. Over the past 10 years, this metric has ranged from a low of 8.62 to a high of 19.63. The Biotechnology industry median PS Ratio is 9.49. OneSource Specialty Pharma's value of 11.04 is 16.3% above this industry median. Based on the distribution chart, OneSource Specialty Pharma ranks #499 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OneSource Specialty Pharma ranks #499 out of 931 companies for PS Ratio. This places OneSource Specialty Pharma in the lower half of its industry. The industry median PS Ratio is 9.49. OneSource Specialty Pharma's value of 11.04 is 16.3% above this benchmark. Historically, OneSource Specialty Pharma's own PS Ratio has ranged from 8.62 to 19.63 over the past decade. While the company's 10-year median is 13.17 vs. the industry median of 9.49, OneSource Specialty Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OneSource Specialty Pharma's current PS Ratio of 11.04 is 16.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on OneSource Specialty Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OneSource Specialty Pharma's current PS Ratio is 11.04, which is 16% below median its own 10-year median of 13.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (NSE:ONESOURCE) has a current PS Ratio of 11.04. The current PS Ratio is 11.04, which is 16% below median its 10-year median of 13.17 and 16.3% above the Biotechnology industry median of 9.49. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For OneSource Specialty Pharma (NSE:ONESOURCE), the current PS Ratio is 11.04 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score
Get the complete analysis for NSE:ONESOURCE
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONESOURCE has been successfully added to your 
